摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-iodophenylmagnesium chloride | 571903-63-4

中文名称
——
中文别名
——
英文名称
4-iodophenylmagnesium chloride
英文别名
chloro(4-iodophenyl)magnesium
4-iodophenylmagnesium chloride化学式
CAS
571903-63-4
化学式
C6H4ClIMg
mdl
——
分子量
262.76
InChiKey
DEWVWIMTYFUSCH-UHFFFAOYSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.77
  • 重原子数:
    9.0
  • 可旋转键数:
    1.0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    0.0
  • 氢给体数:
    0.0
  • 氢受体数:
    0.0

反应信息

  • 作为反应物:
    描述:
    3,6-di(piperidin-1-yl)-9H-xanthen-9-one4-iodophenylmagnesium chloride四氢呋喃 为溶剂, 以90%的产率得到1-[9-(4-Iodophenyl)-6-piperidin-1-ium-1-ylidenexanthen-3-yl]piperidine;chloride
    参考文献:
    名称:
    具有环胺取代基的罗莎胺的合成和光谱性质。
    摘要:
    rosamines A和若丹明B之间存在紧密的结构相似性,但rosamine类中的各种结构及其光谱特性尚未深入研究。该手稿描述了一种简明的,可扩展的溶液相方法,可得到包括一些水溶性衍生物的罗莎明1-5和12-15。在一个测试案例(针对15个案例)中,还形成了一个示例性的蛋白质偶联物。在整个过程中,这些产物被分离和纯化,并且发现合成是可扩展的。此外,具有这些环胺取代基的罗莎胺显示出溶剂依赖性的荧光强度,并且在氯化烃中具有高的量子产率。在某些情况下,环胺取代基的性质显示出以pH依赖的方式调节母体分子的荧光。这些胺取代基的环大小也与其某些光谱性质相关。由一些加成产物1-5制备了几种水溶性的罗萨明,其中的15个之一通过酰胺键与抗生物素蛋白有效地缀合。15和15-亲和素在水性介质中的光谱性质非常相似。
    DOI:
    10.1021/jo800902j
  • 作为产物:
    参考文献:
    名称:
    具有环胺取代基的罗莎胺的合成和光谱性质。
    摘要:
    rosamines A和若丹明B之间存在紧密的结构相似性,但rosamine类中的各种结构及其光谱特性尚未深入研究。该手稿描述了一种简明的,可扩展的溶液相方法,可得到包括一些水溶性衍生物的罗莎明1-5和12-15。在一个测试案例(针对15个案例)中,还形成了一个示例性的蛋白质偶联物。在整个过程中,这些产物被分离和纯化,并且发现合成是可扩展的。此外,具有这些环胺取代基的罗莎胺显示出溶剂依赖性的荧光强度,并且在氯化烃中具有高的量子产率。在某些情况下,环胺取代基的性质显示出以pH依赖的方式调节母体分子的荧光。这些胺取代基的环大小也与其某些光谱性质相关。由一些加成产物1-5制备了几种水溶性的罗萨明,其中的15个之一通过酰胺键与抗生物素蛋白有效地缀合。15和15-亲和素在水性介质中的光谱性质非常相似。
    DOI:
    10.1021/jo800902j
点击查看最新优质反应信息

文献信息

  • Meerwein's Reagent Mediated, Significantly Enhanced Nucleophilic Fluorination on Alkoxysilanes
    作者:Toyoshi Shimada、Yogesh Jorapur
    DOI:10.1055/s-0031-1290757
    日期:2012.4
    We developed a new facile method to fluorosilanes from alkoxysilanes using Meerwein’s reagent. Our protocol afforded fluo­rosilanes in excellent yields in various organic solvents including acetonitrile under mild reaction conditions at room temperature. We also proposed a reaction mechanism with the probable silyloxonium intermediates.
    我们开发了一种使用 Meerwein 试剂从烷氧基硅烷中制备硅烷的简便方法。我们的方案在室温温和反应条件下,在包括乙腈在内的各种有机溶剂中以优异的产率提供硅烷。我们还提出了可能的甲硅烷基氧中间体的反应机制。
  • [EN] ROSAMINE DERIVATIVES AS AGENTS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE ROSAMINE COMME AGENTS POUR LE TRAITEMENT D'UN CANCER
    申请人:CANCER RES INITIATIVES FOUNDAT
    公开号:WO2010033011A1
    公开(公告)日:2010-03-25
    The present invention relates to a new class of rosamine derivatives, in one embodiment, the compounds have the structure (I) or any pharmaceutically acceptable salt or solvate thereof, wherein: R1 represents aryl, Het1 or C1-6 alkyl, which latter group is optionally substituted by aryl or Het2; R2a and R2b together form C3.8n-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo, C1-4 alkyl, C(O)OH and C(O)O-C1-4, alkyl.and which alkylene group is optionally interrupted by X1; R3a and R3b together form C3-6 /7-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo, C1-4 alkyl, C(O)OH and C(O)O-C1-4 alkyl, and which alkylene group is optionally interrupted by X2; X1 and X2 independently represent O, S, or NR4; R4 represents, independently at each occurrence, H, C(O)OR5, C(0)R6a, C(O)N(R6b)R6c or C1-6, alkyl, which latter group is optionally substituted by one or more substituents selected from halo, aryl and Het3 or is substituted by a single C(0)0R1a group; R4a represents H or C1-4 alkyl; R5 represents aryl, Het4 or C1-6 alkyl optionally substituted by one or more substituents selected from halo, aryl and Het5; R5e to R6d independently represent H or R5; each aryl independently represents a C6-10 carbocyclic aromatic group, which group may comprise either one or two rings and may be substituted by one or more substituents selected from halo, CN, C1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR7, phenyl, naphthyl and Het6) and OR8; R7 and R8 independently represent H, C1-4 alkyl (optionally substituted by one or more halo groups or by a single phenyl or C(O)OR8a substituent), Het7, phenyl or naphthyl; R8a represents H or C1-4 alkyl; Het1 to Het7 independently represent 5- to 10-membered aromatic, fully saturated or partially unsaturated heterocyclic groups containing one or.more heteroatoms selected from oxygen, nitrogen and/or sulfur, which heterocyclic groups may comprise one or two rings and may be substituted by one or more substituents selected from Halo, CN, C1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR9 and phenyl) and OR10; R9 and R10 independently represent H, C1-4 alkyl or phenyl; unless otherwise specified, alkyl groups are optionally substituted by one or more halo atoms; and A' represents a pharmaceutically acceptable anion. Also disclosed are methods for making and using ' compounds as well as pharmaceutical compositions.
    本发明涉及一类新的罗萨明衍生物,其中在一个实施例中,化合物具有结构(I)或其任何药学上可接受的盐或溶剂,其中:R1代表芳基、Het1或C1-6烷基,后者可由芳基或Het2取代;R2a和R2b一起形成C3.8n-烷基,该烷基可由卤素、C1-4烷基、C(O)OH和C(O)O-C1-4烷基中选择的一个或多个取代基取代,并且该烷基可由X1中断;R3a和R3b一起形成C3-6/7-烷基,该烷基可由卤素、C1-4烷基、C(O)OH和C(O)O-C1-4烷基中选择的一个或多个取代基取代,并且该烷基可由X2中断;X1和X2独立地表示O、S或NR4;R4在每次出现时独立地表示H、C(O)OR5、C(0)R6a、C(O)N(R6b)R6c或C1-6烷基,后者可由卤素、芳基和Het3中选择的一个或多个取代基取代,或者由单个C(0)0R1a基团取代;R4a表示H或C1-4烷基;R5代表芳基、Het4或C1-6烷基,可由卤素、芳基和Het5中选择的一个或多个取代基取代;R5e到R6d独立地表示H或R5;每个芳基独立地表示一个含有6-10个碳环芳族的芳基,该芳基可能包含一个或两个环,并且可能被一个或多个取代基如卤素、CN、C1-6烷基(后者可由一个或多个取代基如卤素、OR7、苯基、基和Het6取代)和OR8取代;R7和R8独立地表示H、C1-4烷基(可由一个或多个卤素基或单个苯基或C(O)OR8a取代基取代)、Het7、苯基或基;R8a表示H或C1-4烷基;Het1到Het7独立地表示含有一个或多个异氧、氮和/或的芳族、完全饱和或部分不饱和的杂环基,这些杂环基可能包含一个或两个环,并且可能被一个或多个取代基如卤素、CN、C1-6烷基(后者可由一个或多个取代基如卤素、OR9和苯基取代)和OR10取代;R9和R10独立地表示H、C1-4烷基或苯基;除非另有规定,烷基可能由一个或多个卤素原子取代;A'表示药学上可接受的阴离子。还公开了制备和使用该化合物以及制药组合物的方法。
  • A New Method for the Selective Amination of 1,3- and 1,4-Dinitrobenzenes and Protected Nitroanilines Leading to Polyfunctional 1,3- and 1,4-Disubstituted Anilines
    作者:Paul Knochel、Ioannis Sapountzis
    DOI:10.1055/s-2004-820043
    日期:——
    The addition of functionalized arylmagnesium reagents to dinitrobenzenes and protected nitroanilines at -20 °C in THF ­furnishes after a reductive workup polyfunctional diarylamines in 47-92% yield.
    在-20 °C的四氢呋喃中,将官能化的芳基试剂加入二硝基苯和受保护的硝基苯胺中,经过还原反应,可得到多官能二芳基胺,收率为 47-92%。
  • 一种1-(4-碘苯基)-5-氯异苯并呋喃的合成方法
    申请人:常州大学
    公开号:CN105801539A
    公开(公告)日:2016-07-27
    本发明涉及一种化合物的合成方法,一种1?(4?碘苯基)?5?异苯并呋喃的合成方法。该方法通过氧化、缩合等一些列反应制得1?(4?碘苯基)?5?异苯并呋喃,此方法反应条件温和、收率高。
  • ROSAMINE DERIVATIVES AS AGENTS FOR THE TREATMENT OF CANCER
    申请人:Lee Hong Boon
    公开号:US20110212955A1
    公开(公告)日:2011-09-01
    The present invention relates to a new class of rosamine derivatives, in one embodiment, the compounds have the structure (I) or any pharmaceutically acceptable salt or solvate thereof, wherein: R 1 represents aryl, Het 1 or C 1-6 alkyl, which latter group is optionally substituted by aryl or Het 2 ; R 2a and R 2b together form C 3.8 n-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo, C 1-4 alkyl, C(O)OH and C(O)O—C 1-4 , alkyl and which alkylene group is optionally interrupted by X 1 ; R 3a and R 3b together form C 3-6 /7-alkylene, which alkylene group is optionally substituted by one or more substituents selected from halo. C 1-4 alkyl, C(O)OH and C(O)O—C 1-4 alkyl, and which alkylene group is optionally interrupted by X 2 ; X 1 and X 2 independently represent O, S, or NR 4 ; R 4 represents, independently at each occurrence, H, C(O)OR 5 , C(O)R 6a , C(O)N(R 6b )R 6c or C 1-6 , alkyl, which latter group is optionally substituted by one or more substituents selected from halo, aryl and Het 3 or is substituted by a single C(O)OR 1a group; R 4a represents H or C 1-4 alkyl; R 5 represents aryl, Het 4 or C 1-6 alkyl optionally substituted by one or more substituents selected from halo, aryl and Het 5 ; R 5e to R 6d independently represent H or R 5 ; each aryl independently represents a C 6-10 carbocylic aromatic group, which group may comprise either one or two rings and may be substituted by one or more substituents selected from halo, CN, C 1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR 7 , phenyl, napthyl and Het 6 ) and OR 8 ; R 7 and R 8 independently represent H, C 1-4 alkyl (optionally substituted by one or more halo groups or by a single phenyl or C(O)OR 8a substituent), Het 7 , phenyl or naphthyl; R 8a represents H or C 1-4 alkyl; Het 1 to Het 7 independently represent 5- to 10-membered aromatic, fully saturated or partially unsaturated heterocyclic groups containing one or more heteroatoms selected from oxygen, nitrogen and/or sulphur, which heterocyclic groups may comprise one or two rings and may be substituted by one or more substituents selected from Halo, CN, C 1-6 alkyl (which latter group is optionally substituted by one or more substituents selected from halo, OR 9 and phenyl) and OR 10 ; R 9 and R 10 independently represent H, C 1-4 alkyl or phenyl; unless otherwise specified, alkyl groups are optionally substituted by one or more halo atoms; and A′ represents a pharmaceutically acceptable anion. Also disclosed are methods for making and using compounds as well as pharmaceutical compositions.
    本发明涉及一类新的罗萨明衍生物,其中在一种实施例中,化合物具有结构式(I)或其任何药学上可接受的盐或溶剂,其中:R1代表芳基,Het1或C1-6烷基,后一群基团可以被芳基或Het2取代;R2a和R2b共同形成C3.8n-烷基,该烷基可以被来自卤素,C1-4烷基,C(O)OH和C(O)O-C1-4烷基中的一个或多个取代基取代,并且该烷基可以被X1中断;R3a和R3b共同形成C3-6 / 7-烷基,该烷基可以被来自卤素,C1-4烷基,C(O)OH和C(O)O-C1-4烷基中的一个或多个取代基取代,并且该烷基可以被X2中断;X1和X2独立地表示O,S或NR4;R4在每次出现时独立地表示H,C(O)OR5,C(O)R6a,C(O)N(R6b)R6c或C1-6烷基,后一群基团可以被一个或多个来自卤素,芳基和Het3的取代基所取代,或被一个单独的C(O)OR1a基团所取代;R4a表示H或C1-4烷基;R5表示芳基,Het4或C1-6烷基,后一群基团可以被一个或多个来自卤素,芳基和Het5的取代基所取代;R5到R6d独立地表示H或R5;每个芳基独立地表示C6-10碳环芳基,该芳基可以包含一个或两个环,并且可以被一个或多个来自卤素,CN,C1-6烷基(后一群基团可以被一个或多个来自卤素,OR7,苯基,基和Het6的取代基所取代)和OR8的取代基所取代;R7和R8独立地表示H,C1-4烷基(可以被一个或多个卤素或单个苯基或C(O)OR8取代基所取代),Het7,苯基或基;R8a表示H或C1-4烷基;Het1到Het7独立地表示含有一个或多个来自氧,氮和/或的杂原子的5-至10元芳香,完全饱和或部分不饱和的杂环族群,该杂环族群可以包含一个或两个环,并且可以被一个或多个来自卤素,CN,C1-6烷基(后一群基团可以被一个或多个来自卤素,OR9和苯基的取代基所取代)和OR10的取代基所取代;R9和R10独立地表示H,C1-4烷基或苯基;除非另有说明,否则烷基可以被一个或多个卤素原子取代;A'表示药学上可接受的阴离子。还公开了制备和使用化合物以及制药组合物的方法。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫